CRF receptor antagonists and methods relating thereto
AssigneeNeurocrine Biosciences, Inc.
InventorsMustapha Haddach, John Patrick Williams, Michael K. Schwaebe
Life of this patent
Estimating the term…
Abstract
CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animal, such as stroke. The CRF receptor antagonists of this invention have the following structure: 1 including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein m, R, R1, R2, A, X, Y and Z are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.
Claims23
A compound having the following structure:
- the following structure (I):
- 25
- or a stereoisomer, prodrug or pharmaceutically acceptable salt thereof,
- wherein:
- X is nitrogen or CR3;
- Z is O, S or NR4;
- Y is N, NR5 or O;
- A is O, S, or NR6;
- “----” represents an optional double bond;
- R is an optional substituent which, at each occurrence, is independently alkyl, aryl, heteroaryl, alkylidenyl, arylalkyl or heteroarylalkyl, wherein m is 0, 1, 2 or 3 and represents the number of R substituents;
- R1 is alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl;
- R2 is hydrogen, alkyl, substituted alkyl, alkoxy or thioalkyl;
- R3 is hydrogen, halogen, alkyl or substituted alkyl;
- R4 is hydrogen, cyano, nitro, alkyl or substituted alkyl;
- R5 is hydrogen, alkyl or substituted alkyl;
- and
- R6 is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl.
Dependencies are inferred from the claim text.